NR3C1 and Miyoshi myopathy: In a study on dexamethasone-based MM treatment and NR3C1 [23], the clinical effect of expression levels of NR3C1 was investigated with gene expression profiling (GEP) for 351 patients with initial GEP data and 130 patients with relapse.